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Cartilage is essential for the proper formation, growth, and function of long bones. In the process 
of endochondral ossification, cartilage serves a pre-cursor to long bone. Many studies have 
primarily focused on the transcription factors, growth factors, and signaling molecules that 
regulate this process. In recent years, epigenetic mechanisms have surfaced as key regulatory 
elements of gene expression. Some important epigenetic mechanisms include DNA methylation 
and post-translational modification of histone residues, such as histone acetylation and histone 
methylation.  Our research focuses on a unique histone methyltransferases known as disruptor of 
telomeric silencing 1-like (Dot1L) and its role in embryonic and postnatal skeletal development. 
Genetic variants of Dot1L have been associated with skeletal growth, human height, and 
cartilage degeneration. Dot1L’s enzymatic activity catalyzes the methylation of lysine residue 79 
in histone H3 and is associated with gene activation. There remains a gap in our knowledge 
regarding epigenetic regulators of cartilage development and endochondral ossification. For this 
reason, our research aims at understanding the role of Dot1L in regulating endochondral 
ossification in growth plate cartilage and its implications in skeletal growth. We utilize a Cre 
recombinase system to genetically inactivate the Dot1L gene in embryonic and postnatal 
cartilage and perform phenotypic and histological analyses and comparisons of the skeletons of 
control mice and mice expressing loss of Dot1L in cartilage. Results show that loss of Dot1L in 
mice expressing the Cre enzyme impairs skeletal growth. In addition, preliminary histological 
analyses of growth plate cartilage from mice with postnatal loss of Dot1L in cartilage suggest 






Cartilage plays an important role in the formation, growth, and function of embryonic 
development and post-natal growth, acting as a precursor to long bones. The majority of cartilage 
structure and function is regulated by chondrocytes, which are cells responsible for secreting the 
extracellular matrix (ECM). Chondrocytes of articular (joint) cartilage have distinct functions 
from chondrocytes of the growth plate. Growth plate chondrocytes regulate the growth of 
epiphyseal plates. Chondrocytes are metabolically active cells, since they are responsible for 
producing ECM components and are derived from mesenchymal stem cells (MSCs) (Akkiraju 
and Nohe, 2015). The replacement of cartilage by bone occurs in the growth plate, a transient 
structure, and is regulated by key regulatory and transcription factors, which will be discussed in 
greater depth later on. 
The process by which cartilage in the growth plate of longitudinal bones is gradually 
replaced by bone is known as endochondral ossification. Chondrocytes undergo proliferation, 
hypertrophy, and apoptosis. The cartilaginous scaffold provides a surface for attachment of 
osteoblasts, which replace cartilage with bone. Because of the importance of chondrocyte 
differentiation in the formation and longitudinal growth of the skeleton, disruption in the 
regulation of endochondral ossification will result in stunted growth or bone deformities. We 
therefore look at key regulatory factors to better understand the regulation of endochondral 
ossification in growth plate cartilage. 
Components and origin of cartilage 
 Classified as a connective tissue found throughout the body, cartilage functions in 
connecting and supporting bones. It has unique properties such as tensile stretch and mechanical 
properties that can be attributed to the organization of the extracellular matrix (ECM) (Horkay, 
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2012). The ECM is made up 10-25% collagen, 5-15% proteoglycans, 70-80% water, and smaller 
concentrations of noncollagenous proteins and glycoproteins (Horkay, 2012). Collagens are 
macromolecules responsible for stabilizing the matrix by providing tensile and shear strength to 
the tissue (Akkiraju and Nohe, 2015). Specifically, type II collagen is the major fibrous 
component responsible for providing cartilage’s shear strength. Imbedded within the fibrous 
network of collagen are charged proteoglycans. The major proteoglycan in cartilage is the 
aggrecan molecule, which interacts with hyaluronic acid and contributes to the proper 
functioning of articular cartilage by endowing it with load-bearing properties (Horkay, 2012). As 
previously mentioned, chondrocytes are the cells responsible for producing components of the 
ECM. Chondrocytes facilitate fluid exchange within the matrix to maintain proper cartilage 
functions. This fluid exchange is important for abruption of nutrients and removal of waste 
products (Horkay, 2012). Chondrocytes are the cells that undergo endochondral ossification 
during bone growth and repair. Despite the ability of cartilage to undergo repair, it is limited in 
its capacity to repair damage due to its avascular structure, which causes slow healing, and the 
restrictions placed by the fibrous structure of the collagenous network.  
Figure 1- Components of Cartilage 
 
The diagram above shows the components of cartilage, specifically the interactions between 
Type II collagen fibril, proteoglycans and hyaluronic acid (HA). 
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 There are different types of cartilage specialized to perform different functions in the 
body. For example, articular cartilage functions to protect the ends of long bones and joints by 
providing a lubricated surface to reduce friction during movements. On the other hand, growth 
plate cartilage provides the template for long bone formation. This paper puts an emphasis on 
studying the regulatory factors that dictate endochondral ossification, which occurs in the growth 
plate. During this process, the ECM of chondrocytes transition from deposits of collagen 2 
(Col2) to collagen X (ColX), which serves as the base for osteoblast invasion (Li et al., 2015). 
To better understand the regulation of growth plate cartilage, we first look at the organization of 
it. 
Transient structure of the growth plate and regulatory transcriptional factors 
In longitudinal bones, the growth plate is a transient structure where chondrocytes 
undergo endochondral ossification. Chondrocytes undergo successive stages of proliferation, 
hypertrophy (cell maturation), and apoptosis. Thus, cartilage is important since it provides a 
stable template for bone formation and is the source of longitudinal bone growth (Mackie et al., 
2008). The transient nature of the growth plate consists of several histologically and functionally 
distinct zones within the structure, each of which is regulated by transcription factors that 









Figure 2- Organization of Growth Plate Cartilage 
 
Growth plate organization depicts different zones of chondrocyte differentiation, starting from 
resting zone all the way to zone of ossification. 
 
The resting zone is furthest away from the ossification front, where cartilage is replaced 
by bone. Stem-cell like precursors lie in the resting zone. These cells are capable of self-renewal 
and, more importantly, gives rise to proliferative chondrocytes (Luis et al., 2016). In the zone of 
proliferation, proliferating cells become flattened as they begin to arrange themselves into 
multicellular clusters (Mackie et al., 2008). The proliferative zone secretes factors that regulate a 
number of genes. Sex-determining region Y (SRY)-box 9, or Sox9, is the master transcriptional 
factor of cartilage. Sox9 is expressed by proliferative cells and is responsible for inducing the 
expression of one of the major components of cartilage matrix, type II collagen (Col2a) (Mackie, 
et al. 2008). Col2a and Agreccan (Agc) are also found in proliferating chondrocytes. These genes 
are specific to cartilage. Col2a encodes for type II collagen, a major component of the 
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chondrocyte’s extracellular matrix (Mackie et al., 2008).  As the cells undergo maturation, they 
begin secreting type X collagen (ColX), vascular endothelial growth factor (VegF), and matrix 
metalloproteinase (Mmp13). ColX codes for the matrix of hypertrophic chondrocytes and VegF 
is a growth factor that facilitates vascular invasion of growth cartilage in the hypertrophic zone. 
Since cartilage is an avascular structure, VegF is an important growth factor whose secretion is 
characteristic of hypertrophic chondrocytes. In addition, Runt-related transcription factor 2 
(Runx2) is a transcription factor necessary for hypertrophy of chondrocytes (Nishimura et al., 
2018). As the chondrocytes undergo apoptosis, their matrix remains and becomes a template for 
the formation of new bone. Mmp13 is one of the enzymes that degrade the cartilaginous matrix, 
making room for osteoblasts to replace it with bone and allow blood vessels to come in 
(Nishimura et al., 2018). 
Figure 3- Model of endochondral bone formation 
 
Process of chondrocyte differentiation involves important markers of each stage of 
differentiation. Markers of each stage are shown. Sox9 is a key regulatory transcription factor in 
the differentiation of cartilage. Col2a1 codes for type II collagen, which forms the matrix of 
prehypertrophic chondrocytes. As chondrocytes proliferate, their matrix is replaced by ColX. 
 
 As depicted by the schematic above, the process of endochondral ossification is tightly 
regulated by a series of transcription and growth factors. If disrupted, stunted growth or bone 
deformities may present, since bone will no longer be able to replace cartilage, resulting in no 
longitudinal growth of bone. Although there are many studies on the transcriptional regulation of 
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this complex process, there is little known about the epigenetic controls. Thus, this research 
further explores the epigenetic controls of endochondral ossification in the growth plate in vivo. 
Epigenetic controls as a higher level of regulation for gene expression 
 Epigenetic controls refer to control of gene expression outside of altering the genetic 
sequence (Barter et al., 2012). Modifications involve the regulated additions of chemical groups 
to DNA (DNA methylation) and histones (histone modification). Together, these mechanisms 
allow the cell to adapt to environmental changes and are often inherited during cell division 
(Barter et al., 2012). Specific enzymes, called writers, dictate these modifications. Effector 
proteins, or readers, recognize the modifications. Finally, enzymes called erasers are responsible 
for removing the marks of modification, rendering epigenetic marks reversible (Nicholson et al., 
2015). Writers, readers, and erasers work together to control post-translational modifications 
(PTMs). 
 One of the most well documented epigenetic regulatory systems is DNA methylation, 
which is conserved between species (Hata, 2015). DNA methylation involves the addition of a 
methyl group to DNA at CpG dinucleotides on the carbon 5 position of cytosine (Hata, 2015). 
This type of methylation converts cytosine to 5-methylcytosine and is regulated by DNA 
methyltransferases. Methylation at the promoter region of genes prevents certain transcription 
factors from binding to binding elements, which represses transcription (Hata, 2015). Several 
studies have been done to assess the relationship between DNA methylation and cartilage 
degeneration, including osteoarthritis (OA). In patients exhibiting OA, damaged chondrocytes 
show an increased level of methylation in the promoter region of the gene Sox9 (the master 
transcriptional regulator of cartilage) (Hata, 2015). Hypermethylation of this gene is associated 
with decreased Sox9 expression, and subsequently impaired chondrogenesis.  
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Histones modification, another illustration of PTM, is an example of a chromatin 
modification. Chromatin refers to the protein/DNA complex, in which the histone is the special 
protein that encompasses the DNA double helix (Annunziato, 2008). The basic repeating 
structural unit of chromatin is the nucleosome, which is comprised of eight histone proteins and 
about 146 base pairs of DNA (Van Holde, 1988; Wolffe; 1999). Nucleosomes are made up of a 
dimer of each of the following histones: H2A, H2B, H3, and H4 (Annunziato, 2008). The 
histones come together to form an octamer, which binds and wraps about 146 bp of DNA 
(Annunziato, 2008). Histone H1 wraps around another 20 base pairs, which forms two full turns 
around the octamer, forming the complete structure known as a chromatosome (Annunziato, 
2008). Histones are positively charged proteins that bind tightly to the negatively charged 
phosphate groups of the phosphate-sugar backbone of DNA. 
Figure 4- Overview of histone complex 
 
Histones H2A, H2B, H3, and H4 come together to form an octamer. Histone complex binds and 
wraps 146 bp of DNA (Pearson Education, 2012). 
Djunaedi 12 
Histones undergo post-translational modifications, such as acetylation, phosphorylation, 
ubiquitination, and methylation. Acetylation of histones occurs when an acetyl group is added to 
positively charged lysine residues on the N-tail of histone H3 (Hata, 2015), which neutralizes the 
tail and reduces the binding affinity of histone H3 with negatively charged DNA. The decrease in 
the electrostatic bond between the histone and the DNA allows for easy access of transcriptional 
proteins to the transcription sites (Hata, 2015). Thus, histone acetylation is associated with 
increased transcriptional activity. In contrast, histone deacetylation inhibits transcription. The 
enzymes responsible for histone acetylation and histone deacetylation are known as histone 
acetylases (HATs) and histone deacetylases (HDACs), respectively. From a chondrogenic 
standpoint, HAT enzymes are known to positively regulate chondrocyte gene expression through 
interactions with Sox9 (Hata, 2015). Conversely, studies on HDACs reveal that inhibition of 
HDACs protects cartilage from destruction by increasing Col2a gene expression in articular 
chondrocytes (Hata, 2015). Histone acetylation plays an important role in maintaining 
chondrocyte differentiation, as the enzymes responsible for this PTM interacts with the Sox9 
regulatory gene and Col2a1 gene, which codes for matrix collagen. 
Another common protein modification is methylation. This paper focuses primarily on 
regulation of histone methylation and its effects on growth plate chondrocytes. Histone 
methylation plays a key role in the formation of active and inactive genomic regions, and is 
associated with both transcriptional activation and silencing. Whereas acetylation adds acetyl 
groups to lysine residues, methylation adds methyl groups to these residues but does not affect 
their charge. Depending on the target site, histone methylation/demethylation is associated with 
transcriptional repression or activation. Moreover, there are three types of methyl-lysine 
molecular structures: mono methyl (me1), di-methyl (me2), and tri-methyl (me3). After 
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methylation/demethylation, the structure of chromatin can take two forms: a condensed 
transcriptionally “inactive” form and an open “active” form. Despite the fact that the significance 
of histone methylation has been studied in many cellular events including differentiation and 
proliferation, there remains a gap in our knowledge of the regulatory mechanisms of histone 
methylation during chondrocyte differentiation. 
 We discuss one enzyme in particular, disruptor of telomeric silencing like-1 or Dot1L, 
known for its methylation of lysine-79 on histone 3. Genetic variants of the epigenetic regulator 
Dot1L has been associated with skeletal growth and cartilage degeneration (Betancourt 2012 and 
Monteagudo 2017). Methylation of residue 79 in the globular domain of histone 3 lysine by Dot1L 
establishes a more relaxed state in chromatin that results in transcriptional activation. Dot1L is unique 
because it is the only enzyme that adds methyl groups to lysine-79 on histone 3. By studying the 
effects of Dot1L deletion in cartilage, we are able to better understand the cellular and molecular 
mechanisms involved in skeletal differentiation and growth.  
Figure 5- Dot1L-mediated epigenetic regulation 
Dimethylation of lysine 79 in histone 3 (H3K79me2) by Dot1L is associated with open chromatin 
and gene activation. 
 
Regulatory functions of the histone methyltransferase DOT1L 
 Dot1L plays a critical role in regulating gene transcription, development, cell cycle 
progression, somatic reprogamming, and DNA damage repair (Wong et al., 2015). This enzyme 
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is responsible for the methylation of H3K79. Mono- and di-methylation of H3K79 is associated 
with increased gene transcription, whereas tri-methylation results in gene repression (Wong et 
al., 2015). DOT1L is the homolog gene to DOT1 (disruptor of telomeric silencing), which was 
first identified in proteins whose over-expression lead to disruptions in telomeric silencing in 
yeast (Singer et al., 1998). DOT1L has been found in a range of species, including mammals 
such as humans and mice. It functions in adding methyl groups in a non-progressive manner, 
which means it is forced to dissociate and reassociate to H3K79 (Wong et al., 2015). 
 As mentioned before, DOT1L is involved in many cell processes throughout the body. 
Studies on H3K79 methylation on human histones through the use of mass spectrometry shows 
that mono-methylation of H3K79 (H3K79me) is the most abundant form and is associated with 
active gene transcription sites (Wong et al., 2015). In contrast, H3K79me3 is predominantly 
present in silent gene regions in comparison to active regions, which is why tri-methylation of 
H3K79 is associated with gene repression in human cells. H3K79me3 has been linked to cell 
cycle regulation: arrested cells in the G0 phase of the cell cycle show higher levels of 
H3K79me3 (Wong et al., 2015). Inhibition of Dot1L correlates with enhanced reprogramming of 
cell types via silencing of lineage-specific programs of gene expression (Wong et al., 2015). In 
this manner, Dot1L inhibition yields pluripotent stem cell colonies. The wide range of functions 
of Dot1L contributes to its complexity. To add to this complexity, single nucleotide 
polymorphisms (SNPs) of Dot1L in humans have been linked to increased human height (Lango 
Allen, 2010). While inhibition of Dot1L and tissue-specific knockouts have a variety of 
consequences across the human genome, we are focused on the role of Dot1L in skeletal 
development and joint cartilage. 
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The role of Dot1L in skeletal growth and human height 
 In a study done by Betancourt (2012), immunohistochemical staining of the DOT1L 
protein in mice highlights its role in chondrogenic differentiation and adult articular cartilage 
(Betancourt, 2012). Results show silencing of Dot1L inhibits chondrogenesis in vitro, because 
Dot1L knockdown reduces proteoglycan and collagen content, and subsequently mineralization 
during this process (Betancourt, 2012). Loss of Dot1L disrupts the molecular regulation of 
healthy chondrocytes and can lead to osteoarthritic in mice (Monteagudo et al., 2017). 
Furthermore, embryonic stem cells that are Dot1L-deficient present with a global loss of H3K79 
methylation (Jones et al., 2008). Thus, we know that Dot1L and H3K79 methylation play 
important roles in heterochromatin formation and embryonic development. 
H3K79 methylation is associated with transcriptional activation and is a critical 
transcriptional regulator (Kim et al., 2014). The loss of Dot1L results in reduced proliferation of 
cells (Kim et al., 2014), and in cartilage, loss of Dot1L disrupts cartilage homeostasis 
(Monteagudo et al., 2017). Studies link variations in the gene with increased human height 
(Jones et al. 2008 and Simeone and Alberti 2014). In a study by Simeone and Alberti (2014) on 
Epigenetic heredity of human height, genome-wide SNP analyses identified genomic variants 
associated with increased human heights. Among them are variants in Dot1L; polymorphisms in 
Dot1L are associated with taller pubertal stature and accelerated growth rate (Jones et al., 2008). 
Although Dot1L has been linked to skeletal growth and increased human height, the specific role 
of Dot1L in postnatal skeletal development remains obscure. Thus, we developed a mouse model 
where we specifically inactivate Dot1L in cartilage in order to examine its role in vivo in 
regulating endochondral ossification and skeletal growth.  
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Using cartilage specific Cre-recombinase to study the role of Dot1L in vivo 
Our lab developed a mouse model of Dot1L loss of function to explore the physiological 
role of Dot1L in skeletal development.  This model utilizes a Cre-recombinase system to 
specifically inactivate the expression of the Dot1L gene in cartilage in an inducible manner. 
Conditional inactivation of genes in the adult mouse has been plausible with the introduction of 
the Cre-loxP recombination system. Systematically deleting a gene would be lethal to an 
embryonic subject; the Cre-Lox system allows for temporal and tissue-specific control of gene 
deletion. 
The Cre-loxP system involves a conditional allele and a Cre driver, in which the 
conditional allele is the targeted gene located between loxP sites near critical exons or regulatory 
elements of the gene of interest (Henry et al., 2009). The enzyme Cre can recognize specific 
sites, called loxP sites, on a gene sequence. LoxP sites are 34 base pairs long and include a 
spacer region 8 base pairs long as well as two flanking palindromic sequences that are 13 bp long 
each (de la Pena, 2015). Expression of the Cre protein leads to recognition of LoxP sites. The 
Cre protein binds to the 13 bp palindromic regions in the site to form a dimer. This dimer binds 
to another dimer in another loxP site, forming a tetramer. The target sequence is cleaved by the 
Cre protein. The orientation of the loxP sequence is important, since it determines whether the 
Cre will produce a deletion, inversion, or translocation of the target sequence. If the two loxP 
sequences go in the same direction, they produce a deletion. If the sites are oriented in opposite 
directions, they produce an inversion. Finally, if the loxP sites are located in different positions 




Figure 6- Directionality of LoxP Sequences 
Different orientations of LoxP sequences and cleaving produce different results. (A) Two LoxP 
sites oriented in opposite directions produce an inversion. (B) LoxP sites on different positions 
on the same chromosome produce a translocation. (C) LoxP sites go in opposite directions 
produce deletion (de la Pena, 2015). 
 
We are able to engineer transgenic mice that have loss of Dot1L function in cartilage by 
using a cartilage specific Cre, called Aggrecan Cre, as the Cre driver. As mentioned before, 
Aggrecan is a major ECM protein in growth plate cartilage and thus specifically found in 
cartilage (Henry et al. 2009). To delete Dot1L in cartilage, we use an Aggrecan-Cre (Agc-Cre) 
mouse. These transgenic mice are generated such that the expression of Cre is controlled by 
tissue specific regulatory elements, in this case cartilage. Thus, when aggrecan is expressed, so is 
the Cre. To control for the timing of gene activation (i.e. embryonically or postnatally), we create 
a polypeptide that combines the Cre recombinase with a mutant ligand-binding domain of 
estrogen receptor CreERT2 (Henry et al., 2009). Administration of tamoxifen, an estrogen 
analog, activates the Cre recombinase by translocating the Cre from the cytosol into the nucleus. 
Excision of floxed sites and subsequently inactivation of Dot1L becomes dependent upon the 
administration of tamoxifen in Agc-Cre mice expressing the CreERT2 transgene.  
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The schematic above explains how to generate a Cre LoxP mouse. For this research, we use an 
aggrecan-Cre mouse to direct cartilage specific inactivation of Dot1L. Mice with Dot1L are 
floxed, as the LoxP sites are located on either side of exon 5 of the DNA sequence. These mice 
are then bred with aggrecan-Cre mice and produce two different genotypes of mice. Cells with 
active Cre recombinase will have a disruption in the target gene’s function. Cells lacking active 













This research focuses on the Dot1L histone methyltransferase, and its physiological 
effects on postnatal skeletal development. Development of a mouse model of Dot1L loss of 
function enables us to explore the physiological role of Dot1L in skeletal development.  This 
model system utilizes a Cre-recombinase system to specifically inactivate the expression of the 
Dot1L gene in cartilage in an inducible manner. The objective is to validate a mouse model that 
utilizes the Cre recombinase system to genetically inactivate the Dot1L gene in postnatal and 
embryonic cartilage. In addition, phenotypic and histological analyses will be performed on mice 
skeletons with postnatal and embryonic loss of Dot1L expression in cartilage. We will determine 
if the activity of Dot1L methyltransferase in vivo in cartilage is necessary for the regulation of 
endochondral ossification and skeletal growth. Studying the role of Dot1L in regulating 
endochondral ossification is essential to revealing the mechanism by which it epigenetically 
modifies cartilage-specific genes. Loss of Dot1L function in cartilage is hypothesized to impair 











MATERIALS & METHODS 
Dot1L conditional loss of function model and DNA isolation from ear notches 
Dot1L transgenic mice harboring flox (FL) sites flanking exon 5 were used (See Figure 8 
below) (Henry et al. 2009). Aggrecan-CreERT2 mice express Cre recombinase in the nucleus of 
chondrocytes only when injected with tamoxifen, an estrogen analog. Tamoxifen was 
administered in two ways, either indirectly or directly. Embryonic mice were given tamoxifen 
through moms by intraperitoneal injections (IP) on day 15. Postnatally, tamoxifen was injected 
directly into the mice on P5. The amount of tamoxifen administered to each mouse was 
1.5mg/10 grams of body weight. Mice were weighed and amount of tamoxifen delivered was 
determined using the aforementioned ratio. Dot1L floxed mice were mated with mice carrying 
the tamoxifen inducible cartilage specific Cre recombinase gene. Mice were genotyped using 
genomic DNA harvested from ear biopsies. Ear notches were stored at -20°C in 1mL test tubes. 
To isolate the DNA, 50uL of Alkaline Lysis Reagent (25mL water, 62.5uL of 10N sodium 
hydroxide, 10uL of 0.5M disodium EDTA) was added to the tube. Ear fragments were 
completely submerged in the reagent. Tubes were then incubated at 94°C for at least one hour, 
then centrifuged briefly to ensure accumulation of fluid at the bottom of the tube. Next, 50uL of 
Neutralization Reagent (24mL of water, 1mL of 1M Tris-HCl) was added to each tube using a 
pipette. Contents were mixed using the tip of the pipette to break up the tissue. Contents were 






Figure 8- Gene-targeting strategy for the Aggrecan-CreERT2 
 
(Top) Wild-type allele: panel depicts the genomic structure of the mouse aggrecan gene. 
(Bottom) Targetting vector : an inducible Cre recombinase structure (CreERT2) is integrated in 
the 3’ untranslated region (UTR) of the endogenous mouse aggrecan gene. The CreERT2 is 
preceded by a 5’ internal ribosome entry sequence (IRES) and is inserted 63 nucleotides 
downstream of the stop codon of the aggrecan gene. (Henry et al., 2009) 
 
Polymerase Chain Reaction (PCR) 
DNA isolated from ear notches were stored at -20°C. DNA was amplified through 
polymerase chain reaction (PCR). Polymerase chain reaction is a method used to synthesize new 
strands of DNA complementary to the targeted strand of DNA (template strand). Primers (15-30 
bp long) are used to target specific DNA sequences that can be further amplified. PCR was 
performed using primer pairs that specifically amplify (i) wild type Dot1L (200 bp); (ii) floxed 
Dot1L allele (300 bp); (iii) wild type aggrecan (299 bp); and (iv) aggrecan-Cre (200 bp) were 
used10. The following PCR conditions were used for Dot1L: incubation for 5 min at 94 °C, 
followed by 35 amplification cycles of 30 s of denaturation at 94 °C followed by 30 s of 
annealing-elongation at 56 °C and 30 s at 72°C. 2% agarose gel migration of amplicons were 
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performed to determine the specificity of the PCR. Primers used for PCR analysis of Dot1L 
(Integrated DNA Technologies) are listed below: 
PRIMER PRIMER SEQUENCE (5’→ 3’) 
Dot1L-F_floxed (FORWARD PRIMER) CAG AGG ATG ACC TGT TTG TCG 
Dot1L-R_floxed (REVERSE PRIMER) CAT CCA CTT CCT GAA CTC TCG 
 
The following PCR conditions were used for AgcCre: incubation for 2 min at 94 °C, 
followed by 10 amplification cycles of 30 s of denaturation at 94 °C followed by 15 s of 
annealing-elongation at 65°C (-0.5°C per cycle decrease) and 10 s at 68°C. For the next 28 
cycles: 15 s of denaturation at 94 °C followed by 15 s of annealing-elongation at 60°C and 10 
s at 72°C. Samples underwent 2 min in 72°C and were held at 4°C until ready for gel 
electrophoresis. 2% agarose gel migration of amplicons were performed to determine the 
specificity of the PCR. Primers used for PCR analysis of AgcCre (Integrated DNA 
Technologies) are listed below: 
PRIMER PRIMER SEQUENCE (5’→ 3’) 
Aggrecan-F (FORWARD PRIMER) GTG GAG AGT CTT CTG GCA TTA C 
Aggrecan-R (REVERSE PRIMER) CAC TGA GTT CCA CAG ATC CTA AC 
 
Alcian blue staining of histological sections 
To distinguish the cartilage matrix on histological sections, Alcian blue dye (purchased 
from Poly Scientific) was used to visualize the proteoglycan-rich matrix of the cartilage. Alcian 
blue stained the proteoglycan-rich cartilage matrix, while nuclear red stained the nuclei. The blue 
dye specifically forms electrostatic bonds with tissue polyanions, specifically the glycoproteins 
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in the matrix of cartilage (detects sulfated and carboxylated acid mucopolysaccharides). 
Histological sections (7um) of paraffin-embedded hindlimbs were deparaffinized in xylene, then 
rehydrated to distilled water in the following sequence: 10 min in xylene, 5 min in xylene, 2 min 
x 2 in 100% ethanol, 2 min x 2 in 95% ethanol, 2 min in 70% ethanol, 2 min in 50% ethanol, and 
2 in in water. Slides were then placed in 3% acetic acid solution for 3 minutes. Sections were 
then stained with Alcian blue solution pH 2.5 for 20 minutes at 37oC, then washed in water for 
10 minutes and then rinsed in distilled water in a container (water in container was changed 
every minute for 5 minutes). Slides were then counterstained in 0.1% nuclear red fast solution 
for 4 minutes, followed by a wash with copious amounts of tap water for 5 minutes.  Sections 
were then dehydrated (reverse of rehydration process stated above) and mounted with 
appropriate media (Cytoseal 60).  
Immunohistochemistry of paraffin slides 
Immunohistochemistry was performed on paraffin embedded slides of Dot1L floxed 
mice. Sections were deparaffinized in xylene and rehydrated in the following sequence: 10 
min in xylene, 5 min in xylene, 2 x 2 min in 100% ethanol, 2 x 2min in 95% ethanol, 2 min in 
70% ethanol, 2 min in 50% ethanol, and 2 min in water, then indefinitely in PBS. Sections 
were outlined with a hydrophobic pen. Heat-induced epitope retrieval was performed using 
4N HCl solution (solution was prewarmed to 37°C prior to use) or pepsin (added dropwise) 
for 10 minutes in 37°C. Next, sections were treated with 3% hydrogen peroxide in water for 
30 minutes at room temperature to inactivate endogenous peroxidase activity.  Slides were 
rinsed in PBS for 3x5 minutes. Then, sections were made permeable to antibodies by placing 
slides in 0.1% Trixton-X-100 (in PBS) for 10 minutes, followed by washing in PBS for 3x5 
minutes. Next, sections were blocked in normal goat serum for 1 hour at room temperature 
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and incubated overnight at 4 °C with the primary antibodies against Col2a (Abcam, ab58632; 
dilution 1:250 in EPZ-5676-injected mice and 1:400 in cartilage-specific Dot1l knockout 
mice), Dot1L (Novusbio, NB10-40845; dilution 1:750), Sox9 (Abcam, ab185230; dilution 
1:100) or H3K79me2 (Abcam, ab177183; dilution 1:100).  
Slides were washed prior to secondary antibody incubation in PBS for 10 minutes (1X) 
followed by washing in PBS for 10 minutes (3-4X). Secondary antibody incubation occurred 
for 1.5-2 hours at room temperature in appropriate HRP-linked secondary antibody in 1% 
BSA. The following secondary antibodies were used: peroxidase anti-mouse IgG (Vector 
Laboratories PI-2000, 1:200), peroxidase anti-rabbit IgG (Vector Laboratories PI-1000, 
1:200), and Peroxidase anti-goat IgG (Vector Laboratories PI-9500, 1:200). Slides were then 
washed with PBS for 10 minutes (3-4X). The revelation step was done using a Vector AEC 
(RED) Substrate Kit with a Buffer Stock Solution, and AEC Stock Solution, and a Hydrogen 
Peroxidase Solution. Solutions were mixed together in a test tube and 30-50uL of the solution 
was added per slide section. Sections were monitored every 2-3 minutes to watch for color 
changes (browning of sections). Slides were then rinsed in 2-3 changes of PBS and places in 
slide rack for remaining steps. 
Nuclei was counterstained by dipping slides in hematoxylin for 2 seconds and then 
rinsed immediately in copious amounts of distilled water. Slides were drained and dipped in 
ammonia-water for 3-5 seconds and rinsed again in distilled water. Slides were mounted in 
appropriate media and cover slipped. 
Immunofluorescent staining of cultured cells 
Immunoflourescent staining was done on cultured cells. Isolated chondrocytes were fixed 
in formalin, blocked in 1% bovine serum albumin, then incubated with primary antibodies for 
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Col2a, Dot1L, or H3K79me2 for one hour at 37°C. After washes in PBS, cells were incubated 
with fluorescently labeled secondary antibodies (anti-mouse Alexafluor-488, green; or anti-rabbit 
Alexafluor-594, red) for one hour at 37°C. Cells were washed in PBS, then cover slipped prior to 
microscopy. 
Embryonic whole skeletal staining 
Alcian blue staining was used on eviscerated whole mice embryos. The skin and muscles 
were cleared off of these mice before the staining procedure was done. Alcian blue stains for 
cartilage and Alizarin red stains bone. Comparisons between stained control skeletons (Dot1L 
FL/FL) and stained transgenic skeletons (Dot1L FL/FL x AgcCreERT2) allowed us to determine 
the effects of embryonic deletion of Dot1L in cartilage. Solutions used included 100% ethanol 
(EtOH: Pharmco-AAPER Cat#111000200), 100% acetone , glycerol (Fisher Cat# BP229-4), 
Alcian Blue stain (200 mls; 0.03% (w/v) in 80% EtOH, 20% acetic acid), and Alizarin Red stain 
(200 mls; 0.05% in 1% w/v potassium hydroxide). 
 At autopsy, embryos were placed in tap water for 1-5 hours, then scalded in hot tap water 
(~65°C) for 20-30 seconds to allow for easier maceration of the tissue. Forceps were used to 
eviscerate the embryo. Embryos were fixed in 95% EtOH overnight; bubbles were removed 
from body cavity. Embryos were then transferred to 100% acetone and incubated overnight at 
room temperature. Next, cartilage staining was done by placing enough Alcian blue stain to 
cover the body. Embryos were stained overnight at room temperature. The next day, embryos 
were rinsed twice in 95% EtOH and destained in 95% EtOH overnight at room temperature. 
Samples were cleared by placing them in 1% KOH for 1 hour, then counterstaining of bone 
was performed by placing embryos in Alizarin Red stain for 3-4 hours. Samples were then 
cleared by placing them in 1% KOH of decreasing strengths: 1% KOH for 1-3 days at 4°C, 
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80:20 of 1% KOH to glycerol and clear overnight at room temperature, 50:50 of 1% KOH to 
glycerol and cleared overnight at room temperature, 20:80 of 1% KOH to glycerol and clear 
overnight at room temperature, then stored indefinitely in 20:80 of 1% KOH to glycerol. 
RESULTS 
Dot1L expression in primary chondrocytes 
 In order to visualize the expression of Dot1L in chondrocytes, we examined isolated 
chondrocytes from wild-type mice. Chondrocytes that expressed Dot1L in the nucleus would 
validate the efficiency of the Dot1L being used. Antibody staining was used to determine co-
expression of Col2a (type II collagen), Dot1L, and H3K79me2 (dimethylation of lysine-79 on 
H3) in chondrocytes harvested from wild type postnatal day 6 mice. Chondrocytes were 
harvested from the long bones of wild type postnatal day 6 mice. Cells were co-stained using 
Dot1L and Col2a1-specific antibodies. Cultured cells were co-stained in order to distinguish 
between the matrix and the nucleus of the chondrocytes. Co-expression of the two proteins was 
necessary, because Col2a validates the existence of chondrocytes, so Dot1L should also be 
present in these chondrocytes. Col2a (green) is expressed in the matrix whereas Dot1L (red) is 
expressed in the nucleus. Antibodies were used to detect the proteins. Red fluorescence 
correlated with Dot1L expression and green fluorescence correlated with Col2a expression. 
Additionally, nuclear staining of H3K79me2 (dimethylation of lysine-79) was also observed in 
wild type primary mouse chondrocytes (red). The red staining on the right panel depicts activity 





Figure 9- Dot1L expression in primary mouse chondrocytes 
 
(Left) Chondrocytes were harvested from the long bones of wild type postnatal day 6 for 
cultured. Cells were co-stained using Dot1L and Col2a1-specific antibodies. IF microscopy 
showed nuclear expression of Dot1L (red) in mice co-express Dot1L and Col2a. Col2a (green) is 
expressed in the matrix, whereas Dot1L (red) is expressed in the nucleus. (Right) Nuclear 
staining of H3K79me2 (dimethylation of lysine-79) was also observed in wild type primary 
mouse chondrocytes.  
 
Developing a mouse model for the conditional loss of Dot1L function in cartilage 
Dot1L transgenic mice harboring flox sites flanking exon 5 were generated as described 
in Henry et al. These mice were bred with mice carrying the tamoxifen inducible cartilage 
specific Cre recombinase gene (Aggrecan-CREERT2). In order to unqieuly identify each offspring 
from the mouse model, we performed PCR reactions and gel electrophoresis to determine the 
genotypes. DNA from ear notches of each mice were amplified through PCR. Primers specific to 
Dot1L and Agc-Cre were used to amplify specific regions of DNA. Based on the fragment size 
and number, the corresponding genotype could be determined. For example, a WT Dot1L 
transgenic mice presented with one band at 200bp. +/+ denotes wild type genotype. FL/FL 
represents mice homozygous for the floxed Dot1L alleles. Cre/+ is indicative of a mouse that is 
heterozygous for the Cre allele. 
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Figure 10- Breeding of Dot1L Transgenic Mice and AgcCreERT2 Mice 
 
Dot1L transgenic mice harboring loxP sites at exon 5 were bred with mice carryint the 
tamoxifen inducible cartilage specific Cre recombinase gene. Genotypes were determined by 
PCr analyses.+/+ denotes WT; FL/FL denotes mice homozygous for the floxed Dot1L alleles. 
Cre/+ is indicative of a mouse that is heterozygous for the Cre allele. 
 
Validation of cartilage-specific recombinase activity in tamoxifen-treated mice 
 To activate the cartilage-specific Cre recombinase, mice must be injected with tamoxifen, 
an estrogen analog that causes the Cre to translocate into the nucleus. In the nucleus, the Cre 
cleaves the floxed sites it recognizes on Dot1L, rendering the enzyme nonfunctional. Cre both 
deletes Dot1L from the sequence and produces a red fluorescence in mice that lose Dot1L. 
Administration of tamoxifen in mice lacking Dot1L results in aggrecan-expressing cartilage cells 
turning red. Results show red fluorescence around the surface of the femur, which represents the 
articular cartilage. The red fluorescence is seen due to the Ai9 reporter allele in the mice. Ai9 is a 
cre reported mouse that has a loxP STOP cassette that prevents the transcription of a CAG 
promoter driven red fluorescent protein variant (tdTomato). Following Cre-mediated 






Figure 11- Tamoxifen activated CRE Enzyme 
Injection of tamoxifen induces translocation of Cre into the nucleus. Cre is expressed and the 
gene for Dot1L is deleted, producing a red fluorescence to visualize the deletion. (Left) Aggrecan 
expression cells turn red in mice lacking Dot1L. 
 
Embryonic deletion of Dot1L in cartilage impaired skeletal growth 
Embryonic whole skeletal staining was done in order to differentiate between bone and 
cartilage in cleared skeletons. The physical consequences of deletion of Dot1L in cartilage on an 
embryonic level reveals that mice with Agc-Cre are physically shorter than the control mice. 
These mice were not directly given tamoxifen, but rather given tamoxifen indirectly through the 
mom, who received intraperitoneal injection (IP). Deletion of Dot1L was induced by tamoxifen 
on embryonic day 15 and pups were harvested at day 17.5.  In addition to comparing the overall 
lengths of the skeletons, we measured the ratio of ossified femur to overall femur length to 
determine the effects that the loss of Dot1L has on the ossification of femur length. We observed 
a significant difference between the Agc-Cre mice and the control mice. There was a reduction in 
the length of the mineralization of the femur in Agc-Cre mice, which suggests that deletion of 
Dot1L in these mice lead to impaired skeletal growth. Thus, homozygous Dot1LFL/FL mice are 
phenotypically normal. Cartilage-specific inactivation of Dot1L in embryonic and postnatal mice 
by tamoxifen-induced Cre recombinase activity (Dot1LFL/FL:AgcCreERT2) resulted in impaired 
skeletal growth.  
 
Djunaedi 30 
Figure 12- Embryonic comparison of Dot1L deletion in Dot1LFL/FL and 
Dot1LFL/FL;AgcCreERT2 
 
Deletion of Dot1L was induced by tamoxifen on embyronic day 15. Embryos were harvested on 
day 17.5. Intact skeletons were stained with Alcian blue (cartilage) and Alizarin red (bone). 
Staining and quantitative analyses of femur length showed reduced ossified femur length in mice 
with Dot1L loss of function. * p<0.05. 
 
Postnatal deletion of Dot1L in cartilage impaired skeletal growth 
 Qualitative observations were made on the effects of postnatal deletion of Dot1L in 
cartilage. The images depict the effects of Dot1L deletion postnatally on both Control (Dot1L 
FL/FL) and transgenic (Dot1L FL/FL, AgcCre) mice. Pups were injected directly with tamoxifen 
on postnatal day 7-10. Images were taken at 3 weeks and showed impaired growth in Tam-
treated Dot1LFL/FL:AgcCreERT2Ki/+ mice. X-rays showed shortening of tibias in Dot1L deleted 
















Figure 13- Postnatal comparison of Dot1L deletion in Dot1LFL/FL and 
Dot1LFL/FL;AgcCreERT2 
 
Comparisons between control (Dot1LFL/FL) and loss of Dot1L mice depict shortening of 
hindlimbs in Dot1L deleted mice. 
 
Postnatal deletion of Dot1L affected the growth plate structure 
 Histological sections of the mouse tibia growth plates from 3-week-old control and 
Dot1L postnatal loss of function mice were stained with Alcian blue to visualize cartilage. 
Staining depicts that control mice have more residual cartilage than the AgcCre mice, which 
poses the question of how exactly does Dot1L affect endochondral ossification. 






Alcian blue staining of control mice and loss 
of Dot1L mice depict differences in the 
amount of residual cartilage present in the 
growth plate. Mice exhibiting loss of Dot1L 
present with faster bone formation nearer to 
the primary ossification center. 
 
Control Loss of Dot1L Control Loss of Dot1L 
Control Loss of Dot1L 




 Previous studies on the regulation of endochondral ossification and its effects on skeletal 
growth have focused on regulation by systemic and local factors, such as growth hormone, 
insulin-like growth factors (IGFs), thyroid hormone, parathyroid hormone related peptide, 
growth factors, and transcription factors such as Sox9 and Runx2. Recently, however, epigenetic 
control of gene expression and cell behavior has gained attention and the effects of these 
processes on chondrocyte hypertrophy are being studied. One of the key modifications that 
regulate chromatin structure and gene expression is histone acetylation. Histone deacetylase 4 
(HDAC4) is the first histone-modifying enzyme to be associated in cartilage development. 
HDAC4 inhibits hypertrophy by suppressing the activity of Runx2 and MEF2C (myocyte-
specific enhancer factor 2C), which are key transcription factors that promote hypertrophic 
differentiation in endochondral ossification (Vega et al., 2004; Arnold et al., 2007). Mutations in 
the human HDAC4 gene have been associated in a genetic condition with several skeletal 
defects, known as Brachydactyly mental retardation syndrome (Williams et al., 2010). More 
recently, studies have shown HDAC3 is also implicated in growth plate regulation (Bradley et al. 
2013). HDAC3 knockout mice exhibit acceleration of chondrocyte hypertrophy but smaller cell 
size, which was attributed to an increase in the expression of phosphatase-rich repeat 
phosphatase 1 (Phlpp1) in HDAC3-deficient chondrocytes. Phlpp1 levels affect Akt signaling; an 
increase in Phlpp1 levels suppress Akt signaling, which is a positive regulator of chondrocyte 
hypertrophy (Peng et al., 2003; Ulici et al., 2008, 2009; Rokutanda et al., 2009). These studies 
show that there is a direct relationship between the epigenetic regulation of gene expression to 
cell size increase. 
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 Many other posttranslational modifications control histone function, but very few have 
been studied in relation to chondrocyte differentiation. Recent studies have demonstrated that the 
histone methyltransferases ESET is involved in hypertrophy (Lawson et al., 2013; Yang et al., 
2013). ESET has been associated with HDAC4 in suppressing Runx2 activity and subsequently 
hypertrophy. ESET deficient chondrocytes have been shown to undergo accelerated hypertrophy, 
Interestingly enough, our study of loss of Dot1L function in cartilage also shows increased 
hypertrophic differentiation in growth plate chondrocytes. Figure 14 staining shows that 
postnatal deletion of Dot1L affected the growth plate structure. Control mice have more residual 
cartilage than the AgcCre mice. From the histological sections, it appears that Dot1L impairs the 
differentiation of chondrocytes, because staining from mice with a loss of Dot1L show 
chondrocyte differentiation and maturation progressing more rapidly, which is why there is more 
bone formation. This rapid progression from cartilage to bone, however, is not indicative of more 
longitudinal growth, as these mice still appear to be shorter. Thus, the histological analyses of the 
growth plates from mice with postnatal loss of Dot1L suggest that Dot1L is involved in 
controlling chondrocyte differentiation. We hypothesize that Dot1L affects the later stages of 
endochondral ossification, as a smaller hypertrophic layer means there is less cartilage to be 
replaced. In comparison to HDAC KO mice, which are associated with acceleration of 
hypertrophy but smaller cell size, Dot1L KO mice show similar patterns of accelerated 
differentiation, but shorter bone lengths. 
Linking loss of Dot1L to impaired skeletal growth 
It is important to study the mechanisms that control chondrocyte differentiation in order 
to develop a thorough understanding of the formation of longitudinal bones. Defects in the 
process of forming long bones are associated with chondrodysplasias, which are linked to 
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dwarfism and stunted growth. Dot1L is a histone methyltransferases that has been identified as a 
regulator of cartilage health and disease (Monteagudo et al., 2017). Variations of Dot1L are also 
associated with human height (Lango Allen et al., 2010). Dot1L is specifically studied, because 
genome wide association studies (GWAS) have showed that common single variants in the gene 
protect against osteoarthritis, but how the gene affects OA is still unknown. These studies have 
prompted us to investigate the role of Dot1L in embryonic and postnatal skeletal development. 
We address the question “is the activity of Dot1L methyltransferases in cartilage necessary for 
the regulation of endochondral ossification and skeletal growth?” The objective of this research 
was to develop and validate a mouse model that utilizes the Cre recombinase system to 
genetically inactivate the Dot1L gene in embryonic and postnatal cartilage. In addition, we 
aimed to perform phenotypic and histological analyses of skeletons of mice with embryonic and 
postnatal loss of Dot1L expression in cartilage. 
Examination of isolated chondrocytes from the long bones of wild-type postnatal day 6 
mice depict co-staining of Dot1L and Col2a specific antibodies. The antibodies were linked to a 
fluorescent tag in order to help us visualize between the two proteins. Dot1L antibodies 
presented as red tags and Col2a presented as green tags under immunoflourescent microscopy. 
This observation was necessary, because Col2a validates the existence of chondrocytes, since it 
is the gene responsible for making type II collagen. Dot1L staining was important, because we 
needed to distinguish between the matrix and the nucleus. Dot1L is expressed in the nucleus of 
chondrocytes. Thus, Col2a (green) expression corresponds to the matrix of chondrocytes, 
whereas Dot1L (red) staining represents the nucleus. This can be seen in the left panel of Figure 
9. Additional nuclear staining of H3K79me2 was observed in WT primary mouse chondrocytes. 
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Methylation of lysine-79 is indicative of Dot1L activity. The right panel of Figure 9 shows the 
red fluorescence, which corresponds to the activity of Dot1L. 
 Our mouse model utilizes the Cre recombinase system to genetically inactivate the Dot1L 
gene in embryonic and postnatal cartilage. As indicated by the results, the Cre used in our 
experiments was Aggrecan Cre, which is a cartilage specific Cre. Mice expressing Cre 
recombinase were crossed with tdTomato reporter mice to produce mice that expressed red 
fluorescence. Mice that were injected with tamoxifen and lacked Dot1L showed red fluorescence 
around the surface of the femur, which represents articular cartilage. This red fluorescence, 
characteristic of the tdTomato reporter, validates the Cre recombinase activity by using 
immunofluorescence. This means that the cells turn red if the Dot1L gene is deleted. 
 To address the effects of embryonic and postnatal deletion of Dot1L on skeletal growth, 
we looked at the physical consequences of the deletions on mice limbs and whole skeletons. 
Embryonic deletion of Dot1L in cartilage rendered mice with a Dot1LFL/FL; AgcCreERT2 
genotype, compared to the control mice (Dot1LFL/FL). Control mice are phenotypically normal, 
and had no stunted growth, as depicted by whole skeletal staining. In contrast, mice that 
presented with loss of Dot1L embryonically had impaired skeletal growth. This observation was 
supported by comparing the ratios of ossified femur to overall femur length to determine how the 
loss of Dot1L affects ossification of the femur. Quantitative analysis of femur length showed 
reduced ossified femur length in mice with Dot1L loss of function. This indicates that Dot1L is 
necessary in order for ossification to occur. 
Postnatal deletion of Dot1L in cartilage also depicted impaired skeletal growth. This type 
of deletion was represented in a more qualitative manner. Pups who were directly injected with 
tamoxifen had the genotype Dot1LFL/FL; AgcCreERT2. Tamoxifen, as mentioned above, is 
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necessary for the activation of Cre. Once activated, the Cre enzyme is able to target the exon on 
the Dot1L gene responsible for its enzymatic activity, cleaving it and rendering it inactive. X-
rays show that mice treated with tamoxifen have shorter hindlimbs in comparison to control 
mice, who were not treated with tamoxifen.  
Limitations and Future Studies 
 In this study, we observed that loss of Dot1L postnatally and embryonically in mice 
resulted in retarded skeletal growth. However, we did not examine the factors that regulate 
Dot1L activity in growth plate cartilage. Thus, future studies are aimed at understanding the role 
of Dot1L in endochondral ossification and uncovering the genes whose expressions are regulated 
by Dot1L in cartilage. In addition, comprehensive phenotypic, histological, and 
immunohistochemical analyses are underway to determine the specific role of Dot1L in 
chondrocyte differentiation in the growth plate. Studies have suggested that transcriptional 
control may be a mechanism to regulate Dot1L activity (Monteagudo et al., 2017). We know that 
regulation of Dot1L activity directly controls H3K79 methylation and affects gene transcription. 
Dot1L is the only known histone methyltransferases for lysine 79 of histone H3, but there are no 
known demethylases for H3K79. Demethylation of H3K79 occurs through histone renewal and 
cell division. Further studies can identify a specific demethylase of H3K79 through chromatin 
immunoprecipitation (ChIP) procedures. ChIP is a technique used to analyze histone 
modifications (Milne et al. 2014). Through this technique, we may be able to identify a 
demethylase of H3K79 and observe if it affects Dot1L’s control of H3K79, and subsequently, 
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